13F Holdings
中文EN

NVO NOVO NORDISK A S IFRS Annual reports only

Pharmaceutical Preparations · NYSE · SEC CIK 353278 · Reporting currency DKK · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY6.4%
TTM net income YoY1.4%
TTM EPS YoY1.8%
Revenue 3-yr CAGR20.4%
Net income 3-yr CAGR22.6%

Margins

Gross margin81.0%
Operating margin41.3%
Net margin33.1%
FCF margin19.1%
EBITDA margin46.1%

Returns

ROE60.7%
ROA20.3%
ROIC (approx.)37.9%
Asset turnover0.61x

Leverage & solvency

Liabilities / assets64.3%
Debt / equity0.67x
Current ratio0.80x
Interest coverage30.34x

Cash quality & payout

Operating cash flow / net income1.16x
Accruals ratio-3.3%
Payout ratio50.5%
Capex / revenue19.5%

Factor history charts and full statement history on Pro 🔒

Financial statements

Annual Quarterly (none) Export CSV 🔒
Unit: DKK FY2025*2025-12-31FY2024*2024-12-31FY2023*2023-12-31FY2022*2022-12-31FY2021*2021-12-31
Income statement
Revenue309.06B290.40B232.26B176.95B140.80B
Cost of revenue58.79B44.52B35.77B28.45B23.66B
Gross profit250.28B245.88B196.50B148.51B117.14B
R&D expense52.04B48.06B32.44B24.05B17.77B
Operating income127.66B128.34B102.57B74.81B58.64B
Interest expense4.21B1.64B542.00M378.00M289.00M
Pretax income130.54B127.19B104.67B69.06B59.08B
Income tax28.11B26.20B20.99B13.54B11.32B
Net income102.43B100.99B83.68B55.52B47.76B
EBITDA142.32B136.88B109.86B81.36B—
EPS (basic)23.0622.6718.6712.2610.40
EPS (diluted)23.0322.6318.6212.2210.37
Weighted avg. shares (diluted)4.45B4.46B4.49B4.54B4.61B
Balance sheet
Cash & equivalents26.46B15.65B14.39B12.65B10.72B
Receivables70.86B71.95B64.77B50.56B40.64B
Inventory49.62B40.85B31.81B24.39B19.62B
Current assets172.45B161.79B139.65B108.19B85.59B
PP&E, netmay include right-of-use assets (IFRS)208.38B161.68B90.96B66.67B55.36B
Goodwill19.84B20.02B———
Intangibles110.21B90.80B60.41B50.94B43.17B
Total assets542.90B465.63B314.49B241.26B194.51B
Current liabilities215.66B217.61B169.66B120.94B99.52B
Short-term debt12.02B13.11B6.48B1.47B13.68B
Long-term debt118.94B89.67B20.53B24.32B12.96B
Total debt130.96B102.79B27.01B25.78B26.64B
Total liabilities348.86B322.14B207.93B157.77B123.76B
Shareholders' equity194.05B143.49B106.56B83.49B70.75B
Net debt104.49B87.13B12.61B13.13B15.93B
Shares outstanding4.44B4.44B4.46B4.50B4.62B
Cash flow statement
Operating cash flow119.10B120.97B108.91B78.89B55.00B
Capital expenditure60.14B47.16B25.81B12.15B6.33B
Free cash flow58.96B73.80B83.10B66.74B48.66B
Investing cash flow-79.16B-128.90B-43.89B-24.92B-31.61B
Financing cash flow-28.41B8.73B-63.16B-51.80B-25.49B
Depreciation & amortization14.67B8.54B7.29B6.55B—
Stock-based compensation1.44B2.29B2.15B1.54B1.04B
Dividends paid51.76B44.14B31.77B25.30B21.52B
Share buybacks1.39B20.18B29.92B24.09B19.45B

Free plan shows the latest 5 periods; Pro shows all 7 🔒

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.

· Amounts are in the company's reporting currency, DKK, not USD; the site does no currency conversion.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.